Psyence Biomedical (PBM) News Today $0.48 +0.04 (+8.54%) Closing price 04/9/2025 03:58 PM EasternExtended Trading$0.46 -0.02 (-4.39%) As of 04/9/2025 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Psyence Biomedical reports corporate updateApril 3, 2025 | investing.comPsyence BioMed Advances in Psychedelic Medicine with Strategic Growth and Clinical TrialsApril 1, 2025 | tipranks.comPsyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Further Strengthens Scientific Advisory Board With Appointment of Dr. Dan J. SteinMarch 25, 2025 | markets.businessinsider.comPsyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D.March 10, 2025 | globenewswire.comPsyence Biomedical files $75M mixed securities shelfMarch 4, 2025 | markets.businessinsider.comPsyence Biomed Names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory BoardFebruary 26, 2025 | markets.businessinsider.comPsyence Biomed Names Albert P. Garcia-Romeu, Ph.D.February 26, 2025 | globenewswire.comPsyence Biomedical files to sell 3.075M common shares for holdersJanuary 25, 2025 | markets.businessinsider.comPsyence Biomedical Issues Pre-Funded Share Purchase WarrantJanuary 1, 2025 | markets.businessinsider.comPsyence Biomed Announces Closing of $2.0 Million Private PlacementDecember 27, 2024 | globenewswire.comPsyence Biomedical prices 1M shares at $2.00 in private placementDecember 24, 2024 | markets.businessinsider.comPsyence Biomedical Regains Nasdaq Compliance, Fortifying Market PositionDecember 23, 2024 | tipranks.comPsyence Biomedical regains full compliance with Nasdaq requirementsDecember 23, 2024 | markets.businessinsider.comPsyence Biomedical Ltd.: Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing RequirementsDecember 23, 2024 | finanznachrichten.dePsyence Unveils Private PlacementDecember 23, 2024 | baystreet.caPsyence Biomed Announces $2.0 Million Private PlacementDecember 23, 2024 | tmcnet.comPsyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing RequirementsDecember 23, 2024 | globenewswire.comPsyence Biomedical files to sell 10.9M shares of common stock for holdersDecember 22, 2024 | markets.businessinsider.comPsyence Biomedical Advances in Phase IIb Psilocybin Clinical TrialDecember 20, 2024 | markets.businessinsider.comPsyence Biomedical Signs Exclusive Licensing Agreement with Optimi HealthDecember 20, 2024 | markets.businessinsider.comPsyence Biomedical Ltd.: Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical TrialDecember 17, 2024 | finanznachrichten.dePsyence Biomed Highlights Recent Progress on Active Phase IIb Clinical TrialDecember 17, 2024 | globenewswire.comCVS's Sell-Off May Be OverblownDecember 15, 2024 | seekingalpha.comPsyence Biomed Executes Binding Agreements with Optimi Health Corp.December 10, 2024 | globenewswire.comPsyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligationsDecember 6, 2024 | globenewswire.comPsyence Biomedical Boosts Equity to Meet Nasdaq RulesDecember 4, 2024 | markets.businessinsider.comPsyence Biomedical Revises Debt-for-Equity DealDecember 4, 2024 | markets.businessinsider.comPsyence Biomedical Issues Shareholder Update Highlighting Recent ProgressDecember 3, 2024 | globenewswire.comPsyence Biomedical (NASDAQ:PBM) Trading Down 7% - Time to Sell?Psyence Biomedical (NASDAQ:PBM) Trading Down 7% - What's Next?November 27, 2024 | marketbeat.comPsyence announces favorable result on Nasdaq listing qualifications hearingNovember 21, 2024 | markets.businessinsider.comPsyence Biomedical gets extension to show compliance with Nasdaq’s listing rulesNovember 20, 2024 | msn.comPsyence Biomedical Announces Effective Date for 1-for-75 Share ConsolidationNovember 19, 2024 | globenewswire.comPsyence Biomedical Announces Share Consolidation StrategyNovember 14, 2024 | markets.businessinsider.comPsyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from NasdaqNovember 12, 2024 | globenewswire.comPsyence Biomedical Acquires Stake in PsyLabsNovember 2, 2024 | markets.businessinsider.comPsyence Group closes disposal of stake in PsyLabsOctober 31, 2024 | markets.businessinsider.comPsyence Biomedical closes acquisition of Psyence Group’s stake in PsyLabsOctober 31, 2024 | markets.businessinsider.comPsyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabsOctober 31, 2024 | globenewswire.comPsyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group’s Stake in PsyLabsOctober 31, 2024 | markets.businessinsider.comPsyence recruits Empax Center as second trial site for Phase IIb trialOctober 25, 2024 | markets.businessinsider.comPsyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative CareOctober 25, 2024 | globenewswire.comPsyence Biomedical Plans Key Shareholder MeetingOctober 24, 2024 | markets.businessinsider.comPsyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative CareOctober 24, 2024 | globenewswire.comPsyence Group Inc. (PSYGF)October 18, 2024 | finance.yahoo.comPsyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) DevelopmentOctober 17, 2024 | globenewswire.comPsyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence BiomedicalOctober 14, 2024 | globenewswire.comPsyence Biomedical (NASDAQ:PBM) Stock, Short Interest ReportOctober 5, 2024 | benzinga.comPsyence Biomedical (NASDAQ:PBM) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comPsyence Biomed Provides Update on Previously Announced Acquisition of ClairvoyantOctober 4, 2024 | globenewswire.comPsyence Group Inc.: Psyence Group Enters into Agreement to Dispose of Stake in PsyLabsSeptember 20, 2024 | finanznachrichten.de Remove Ads Get Psyence Biomedical News Delivered to You Automatically Sign up to receive the latest news and ratings for PBM and its competitors with MarketBeat's FREE daily newsletter. Email Address PBM Media Mentions By Week PBM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PBM News Sentiment▼0.000.76▲Average Medical News Sentiment PBM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PBM Articles This Week▼21▲PBM Articles Average Week Remove Ads Get Psyence Biomedical News Delivered to You Automatically Sign up to receive the latest news and ratings for PBM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PHAXIAM Therapeutics News Aprea Therapeutics News Athira Pharma News Biomerica News Moleculin Biotech News Citius Pharmaceuticals News Trinity Biotech News GeoVax Labs News BioCardia News BioLineRx News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PBM) was last updated on 4/10/2025 by MarketBeat.com Staff From Our PartnersThe Most Bullish Metric For Stocks (NOT Volume…)Before placing a single trade, Tim Sykes always checks one key bullish metric. It’s the same signal that has s...MillPub | SponsoredTrump’s policies mean HUGE income for investorsThanks to a Trump win… Investors have a HUGE opportunity at new income. The floodgates for U.S. oil prod...The Oxford Club | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredBITCOINYou're not going to believe this. There's a bizarre new way to make money from crypto... ...and it's not...Awesomely, LLC | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThis almost killed Elon Musk (chilling details emerge)Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Psyence Biomedical Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Psyence Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PBM Stock Free PBM Stock Alerts